Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4063264 | 0.85 | NAMPT (0.38) | NAMPTGPR119 | |
| SCHEMBL22616067 | 0.85 | NAMPT (0.38) | NAMPTGPR119 | |
| SCHEMBL22616012 | 0.85 | NAMPT (0.38) | NAMPTGPR119 | |
| SCHEMBL15232540 | 0.80 | SLC6A2 (0.38) | NAMPTGPR119 | |
| SCHEMBL15232537 | 0.80 | SLC6A2 (0.38) | NAMPTGPR119 | |
| Oxalic Acid SCHEMBL23456740 | 0.77 | SLC6A2 (0.36) | NAMPT | |
| SCHEMBL22284411 | 0.77 | NAMPT (0.38) | NAMPT | |
| SCHEMBL14316367 | 0.77 | GPR119 (0.57) | NAMPTGPR119 | |
| SCHEMBL30451669 | 0.77 | GPR119 (0.57) | NAMPTGPR119 | |
| SCHEMBL20077751 | 0.77 | GPR119 (0.57) | NAMPTGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME LLC (US) | 2023-05-23 | — | — | US | disclosed |
| US-10894775-B2 | Piperidine derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2021-01-19 | — | — | US | disclosed |
| US-20200247754-A1 | ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247754-A1 | ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | NR1H2, NR1H3, NR1H4 | NAMPT 4040/4885GPR119 15/4885 |
| US-10894775-B2 | Piperidine derivatives as liver X receptor beta agonists, compositions, and their use | NR1H2, NR1H3, ADRB1 | NAMPT 3925/4885GPR119 7/4885 |
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | NR1H2, NR1H3, NR1H4 | NAMPT 4040/4885GPR119 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.